Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)

BACKGROUND: The combination of a microtubule inhibitor (eribulin) with a nucleoside analog (gemcitabine) may synergistically induce tumor cell death, particularly in triple negative breast cancer (TNBC) characterized by high cell proliferation, aggressive behavior, and chemo-resistance. PATIENTS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellegrino, B., Cavanna, L., Boggiani, D., Zamagni, C., Frassoldati, A., Schirone, A., Caldara, A., Rocca, A., Gori, S., Piacentini, F., Berardi, R., Brandes, A.A., Foglietta, J., Villa, F., Todeschini, R., Tognetto, M., Naldi, N., Bortesi, B., Montemurro, F., Ardizzoni, A., Boni, L., Musolino, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808100/
https://www.ncbi.nlm.nih.gov/pubmed/33399082
http://dx.doi.org/10.1016/j.esmoop.2020.100019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808100/
https://www.ncbi.nlm.nih.gov/pubmed/33399082
http://dx.doi.org/10.1016/j.esmoop.2020.100019

Ejemplares similares